GENE EDIT
Central Hypothesis
“Track gene editing breakthroughs, synthetic organism capabilities, biosecurity risks, and governance gaps in programmable biology.”
Synthetic biology is expanding from designed circuits to programmable cellular logic and partial self-replication, while generative models begin searching circuit architectures; the newest results remain laboratory demonstrations rather than deployed systems.
Collapsing gene synthesis costs and open-source protocols create dual-use risks. Gain-of-function research oversight remains fragmented.
Governance is tightening in some jurisdictions but diverging in scope and timing: the US funding ban is still being implemented, FDA genome-editing safety standards remain draft, EU crop rules ease in 2028, and Japan now criminalizes heritable embryo editing.
The clinical pipeline is broadening across modalities: Casgevy now reaches children age 2+, dual-AAV therapy improved hearing in 16 of 20 evaluable patients, and host-cell discoveries increased nonviral retinal editing up to 8-fold, but durability and delivery barriers remain.
Gene-edited crops bypass GMO regulations in some jurisdictions. CRISPR livestock entering food chain. Food security applications accelerating.
Lab-grown materials replacing petrochemicals. Precision fermentation scaling. Synthetic biology enabling novel materials and chemicals.
DNA can store 215 petabytes per gram. Commercial applications emerging. Read/write costs declining but still prohibitive for mass adoption.
Gut microbiome therapeutics entering clinical trials. Soil microbiome engineering for agriculture. Industrial applications expanding.
Dual-use exposure is widening through three concrete paths: AI-designed sequences may evade known-pathogen matching, mobile CRISPR cargo can spread edits between bacteria, and long viral or repository sequences fall outside current customer screening.
Synbio VC rebounds to $18B. IPO activity recovering. Major M&A as pharma acquires biotech capabilities.
This topic's hunt pipeline cites only these 169 domains — no general web sources.
Government / Regulator
International Organisation
Research / Journal
Primary Lab / Company
Statistical / Data Agency
Non-Profit / Archive
Applies to all topics (119)